Ascent Wealth Partners’s Alnylam Pharmaceuticals ALNY Stock Holding History

Ascent Wealth Partners’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-3,000	Closed	-$219K	–	139
2018 Q4	$219K	Hold	3,000	–	–	0.09%	111
2018 Q3	$263K	Hold	3,000	–	–	0.08%	116
2018 Q2	$295K	Hold	3,000	–	–	0.1%	104
2018 Q1	$357K	Hold	3,000	–	–	0.13%	98
2017 Q4	$381K	Hold	3,000	–	–	0.14%	98
2017 Q3	$352K	Hold	3,000	–	–	0.14%	96
2017 Q2	$239K	Sell	3,000 -970	-24%	-$62K	0.1%	108
2017 Q1	$203K	Buy	+3,970	New	+$183K	0.09%	117

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Ascent Wealth Partners's ALNY Position: Q1 2019 in Review

Ascent Wealth Partners sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2019, closing a stake of 3,000 shares — an estimated $219K sold.

Ascent Wealth Partners first reported a position in ALNY in Q1 2017 and held it in 8 quarters. The position peaked at $381K in Q4 2017. 291 funds tracked by Wall St. Rank hold ALNY as of Q1 2019.

Ascent Wealth Partners reported no remaining Alnylam Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
Ascent Wealth Partners sold 3,000 Alnylam Pharmaceuticals shares in Q1 2019, an estimated $219K.
Ascent Wealth Partners first reported a position in Alnylam Pharmaceuticals in Q1 2017 and held it in 8 quarters.
Ascent Wealth Partners's Alnylam Pharmaceuticals position peaked at $381K in Q4 2017.
291 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2019.

Based on Ascent Wealth Partners's 13F filing for Q1 2019, filed 13 May 2019.